Vaccines against COVID-19

Medicines agencies around the world are collaborating to approve and follow vaccines against COVID-19. Once the vaccines are approved, medicines authorities around the world follow up with monitoring of adverse drug reactions. Read about results, processes and new vaccines against COVID-19 in our three themes or in the question-and-answer below.

Go to theme

Investigations of the AstraZeneca vaccine (Vaxzevria)

The Danish Health Authority has decided to continue the COVID-19 vaccine rollout without the vaccine from AstraZeneca. In this theme, you can read about the investigations of the unusual symptoms that were part of the rationale for this decision.

Go to theme
indgangsikon nr 1

General public

Here you can read about reimbursement, drugs affecting the ability to drive and other topics relevant for the general public.

indgangsikon nr 2


Information on licensing, inspections, fees, company authorisations, clinical trials and more.

indgangsikon nr 3

Healthcare professionals

This section gathers information for doctors, nurses, pharmacies, dentists and other healthcare professionals.


Annual report of the Danish Medicines Agency: The COVID-19 pandemic had a considerable impact on our work in 2020.

26 April 2021

The year 2020 was a year like no other at the Danish Medicines Agency. Both internally and externally, the handling of COVID-19 had a decisive impact on much of our work. However, we managed to retain our European position and to carry through an important reinforcement of our IT landscape, so concludes the Danish Medicines Agency’s annual report for 2020.

EMA: Possible link between the Johnson & Johnson vaccine and unusual symptoms

21 April 2021

EMA to undertake a review of data as to the AstraZeneca vaccine’s efficacy in preventing COVID-19 disease

15 April 2021

EMA: The AstraZeneca vaccine possibly causes rare, serious symptoms – but remains authorised for use

08 April 2021